NCT01376739View on ClinicalTrials.gov

Magnevist Post-marketing Surveillance in Japan

CompletedOBSERVATIONAL
Enrollment

2,051

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Diagnostic Imaging
Interventions
DRUG

Gadopentetate dimeglumine (Magnevist, BAY86-4882)

Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01376739 - Magnevist Post-marketing Surveillance in Japan | Biotech Hunter | Biotech Hunter